Progressive myoclonic epilepsy type 1 (EPM1) …

Epilepsy & Seizures

Updated 05.22.2024
Released 11.11.1996
Expires For CME 05.22.2027

Progressive myoclonic epilepsy type 1

Authors: Pasquale Striano MD PhD, Antonella Riva MD PhD

See Contributor Disclosures

Editor: Solomon L Moshé MD

Progressive myoclonic epilepsy type 1

In This Article

Quick Link

Introduction

Overview

Progressive myoclonic epilepsy type 1 (EPM1) is a progressive myoclonus epilepsy caused by pathogenic, autosomal recessive variants in the cystatin B (CSTB) gene mapped to chromosome 21q22.3. The disease is regarded as the “purest” progressive myoclonus epilepsy due to disabling stimulus-sensitive and action myoclonus and generalized tonic-clonic seizures, whereas cognitive deterioration and cerebellar signs are mild and slowly progressive. Age at onset ranges between 6 and 13 years (mean, 10 years) and a relatively high frequency is observed on the shores of the Baltic and Mediterranean Seas, probably due to founder effects. Widening the knowledge over the molecular basis of this disease may also expand our chance of effective treatment, hence, the field opened by neuroinflammation, which is increasingly becoming a suitable target for precision medicine-based approaches also in this disease.

Key points

	• EPM1 is an autosomal recessive progressive myoclonus epilepsy.
	• It manifests with action and stimulus-sensitive myoclonus, generalized tonic-clonic seizures, mild and slowly progressive cerebellar ataxia, and cognitive deficits. Myoclonic seizures are severe and debilitate teenagers throughout adolescence and early adulthood.
	• It is mainly caused by a homozygous expansion of a dodecamer repeat near the promoter of the cystatin B (CSTB) gene mapped to chromosome 21q22.3. Thus, the diagnosis can be confirmed by appropriate molecular genetic testing.
	• Valproate, levetiracetam, zonisamide, perampanel, benzodiazepines, and topiramate are first-choice antiseizure medications for treatment. Conversely, carbamazepine and derivatives, phenytoin, gabapentin, pregabalin, and vigabatrin are contraindicated.

Historical note and terminology

Progressive myoclonic epilepsy type 1 (EPM1) is also known as Unverricht-Lundborg disease. Heinrich Unverricht was a German physician, born on September 18, 1853, in Breslau; he died on April 22, 1912, in Magdeburg.

Dr. Heinrich Unverricht

Heinrich Unverricht described progressive myoclonic epilepsy in Dorpat, now Tartu, Estonia, where he was Professor of Medicine. (Contributed by Dr. Frederick Andermann.)

He was Professor of Medicine in Dorpat, now Tartu, Estonia. In 1891 he described a family of Baltic German origin in which several siblings suffered from a progressive neurologic disease with prominent myoclonus and generalized seizures. Tremor and rigidity have not been described in his patients (94). He also published a volume named Die Myoclonie (112).

Lundborg, from 1898 to 1910, compiled information on 17 patients afflicted by what is now known as progressive myoclonic epilepsy type 1 (EPM1 disease). They all belonged to one extensive kindred, the "Lister" family in Listerlandet of southern Sweden. He and Blekinge traced the affected family back to the 1700s (72; 73; 74). Lundborg's thesis on “Die progressive Myoklonus-Epilepsie (Unverricht's Myoklonie)” was one of the earliest descriptions of recessive inheritance (73). He had published the names of those affected, and he had concluded that the family had degenerated because of “unwise marriages.” Subsequently, a marriage of relatives was carefully avoided in the group and no more cases occurred. According to Puschmann, Lundborg distinguished three stages of the disorder: Stage 1 began in childhood or early adolescence and consisted of nocturnal attacks of involuntary symmetric muscle twitches, which often were painful, caused anxiety, and reminded Lundborg of clonic, tonic-clonic, or tetanic seizures (94). Patients were awake and conscious during the attacks. Stage 2 appeared a few years later with diurnal tremor, myokymia, and myoclonic or dystonic muscle contractions. Typically, the contractions initially affected the upper extremities symmetrically and subsequently involved lower extremities, head, neck, and finally, all voluntary muscles. Tactile and auditory stimuli elicited and stress aggravated these involuntary muscle contractions. Symptom severity fluctuated markedly from day to day. Gradually, increased muscle tone was noted in the interval between attacks. Stage 3 appeared several years to some decades later with the disappearance of the nocturnal attacks whereas daytime muscle contractions became more and more pronounced. Regularly, marked generalized rigidity developed, leaving some patients utterly stiffened in certain poses, incapable of any voluntary movements. Lundborg noted that the clinical picture of some of his patients in the terminal phase reminded him of Parkinson disease.

Herman Bernhard Lundborg was a Swedish physician, born on April 7, 1868, in Vase, Varmlands lan, and he died in 1943. His radical racist ideas and his influence of Nazi ideology and acts overshadow his contribution to medicine. He was extremely negative to Jewish people and strongly involved in the ideology of racial hygiene. He was also responsible for the massive mapping, The Racial Character of the Swedish Nation, from 1926. He characterized 15% of patients in his work as morally or socially inferior (alcoholic, criminal, wanton, of bad character) and another 9.5% as psychiatrically inferior. He had served as a Professor for Racial Hygiene and he advocated the ideology of race biology. His influence contributed to the implementation of forced sterilization programs in Sweden and his view was that "The future belongs to the racially fine people" (75).

Over the next 80 years, there was a great deal of discussion and misunderstanding of the nature and classification of the progressive myoclonus epilepsies (08; 15; 31; 103; 71; 90; 07; 51; 94), of which EPM1 is the most common. Advances in molecular biology have identified EPM1 disease as a specific genetic disorder encountered in many populations and parts of the globe. It has been described under different names, including Baltic myoclonus or Mediterranean myoclonus, before their identification by genetic studies as the same disorder as EPM1. Similarly, Ramsay Hunt syndrome or dyssynergia cerebellaris myoclonica is no longer considered to be a separate disease (02; 37; 80).

An excellent source of information is an online review of EPM1 by Lehesjoki and Kalviainen (66) and other updates (52).

Clinical manifestations

Presentation and course

Patients with progressive myoclonic epilepsy type 1 (EPM1) are initially normal. Myoclonic jerks make their appearance between the ages of 6 and 18 years, with a peak at 9 to 13 years (86% of patients). The myoclonic jerks are action activated and stimulus sensitive.

Progressive myoclonic epilepsy type 1 (EPM1) disease: clinical manifestations

This 18-year-old girl has progressive myoclonic epilepsy type 1 (EPM1) disease that began at 12 years of age with action myoclonus and generalized tonic-clonic seizures. Despite major antimyoclonic therapy, including valproate,...
Progressive myoclonic epilepsy type 1 (EPM1) - action myoclonus

(A) On execution of a requested movement (“raise you right hand toward the head”) intense repeated myoclonias maximal in the agonist arm muscles are followed by atonias of long (more than 500 ms) duration, with or without multi...
Progressive myoclonic epilepsy type 1: action-activated myoclonus

Myoclonias are elicited by movement on the execution of the requested task. (Myoclonias are elicited by movement on the execution of the requested task. (Contributed by Dr. Pasquale Striano.)
EPM1: Composed figure

(A) Archimedean spiral: drawing is invalidated by action myoclonus. (B) Somatosensory evoked potentials: stimulation of the left median nerve evokes a typical giant wave at the cortical (N33) level; Averaged polygraph: at the a...

They may be provoked by light, physical exertion, and stress. Stimulus-sensitive myoclonus is the first symptom in at least 50% of patients and is an essential feature for diagnosis. They may be focal or multifocal and affect predominantly the proximal muscles of the extremities. They are small and mild, but they may also become so violent as to cause frequent falls. In a study of nine patients with genetically proven EPM1, myoclonus was activated by action but was virtually absent at rest and poorly induced by stimuli. Positive myoclonus was multifocal, often rhythmic and of brief duration, with top-down pyramidal temporospatial propagation (35). Compared with normal subjects, patients with EPM1 demonstrated decreased saccadic gain, increased gain dispersion, and a higher frequency of hypermetric saccades associated with decreased peak velocity (35).

Generalized convulsions, sometimes nocturnal, are initially infrequent and may not occur in all patients. These are at times clonic-tonic-clonic convulsions.

Myoclonus and GTCS progressively worsen over the 3 to 8 years following the onset of the disease. Severe action, reflex, and spontaneous myoclonus predominates and becomes the most incapacitating symptom. It takes the form of continuous shivering-like, small amplitude myoclonus affecting every muscle of the body, including the tongue and mouth. Violent myoclonic jerks erupt out of this “background myoclonic noise,” causing falls and injuries.

Progression to ataxia, incoordination, intention tremor, and dysarthria with mental deterioration are typical late features. However, the severity of the symptoms varies significantly even within affected members of the same family.

Progressive myoclonic epilepsy type 1: finger-to-nose maneuver

The finger-to-nose maneuver is invalidated by marked tremor and slight dysmetria; moreover, shoulder myoclonias could be observed during movement. (Contributed by Dr. Pasquale Striano.)
Progressive myoclonic epilepsy type 1: ataxic gait

Instability in standing up and ataxic, broad-based, gait suggestive of a slight cerebellar involvement. (Contributed by Dr. Pasquale Striano.)

There is a slowly progressive mental deterioration, evaluated as a loss of one IQ point per year (61; 62), though most authors consider that this is usually mild and does not reach the levels of dementia (31). However, three neuropsychological studies demonstrated that patients with EPM1 show significant impairment of abstract reasoning, attention, planning, word fluency, constructive praxis, and visuospatial memory and learning in comparison with controls (32). Moreover, patients have lower scores on all short-term memory and executive function tasks, which are associated with the duration of disease and severity of myoclonus (25; 01).

Overall, the disease tends to stabilize in adulthood but with a severe disability.

Notably, patients who are compound heterozygous for the dodecamer repeat expansion and the c.202C>T mutations have a more severe clinical form of EPM1 than patients homozygous for the expansion mutation. They have an earlier age at onset of symptoms, more severe myoclonus, drug-resistant tonic-clonic seizures, moderate to severe cognitive impairment, and, sometimes, psychiatric symptoms (59; 13). Conversely, atypical presentations with milder, not full-blown, symptomatology and late onset have also been described. Nasri and colleagues described the case of a 50-year-old patient exhibiting progressive myoclonus and cerebellar ataxia, together with anxiety disorders (ie, specific phobia and agoraphobia) due to recurrent initial falls (84). High intra-familial phenotypic variability was also described among those relatives who tested positive for Unverricht-Lundborg disease. Hence, the authors underlined the importance of clinical suspicion in the case of suggestive family history also in older patients.

Prognosis and complications

Patients with Unverricht-Lundborg disease often have comorbidities. Trauma and mental health risks should be especially followed and acted on (108). Nevertheless, the outcome seems related to the severity of the myoclonus, tonic-clonic seizures, and ataxia.

The ataxia is greatly increased by the use of some antiepileptic drugs, notably phenytoin, prescribed to many of these patients in the past. Withdrawal of phenytoin has led to a marked improvement (23). The reason for progression is attributable to the prolongation of negative myoclonus duration (measured as the silent periods on EMG) as well as the increase in its frequency (114).

There is some disagreement as to whether intelligence remains normal (29) or may deteriorate even when optimal antiepileptic and antimyoclonic treatments are used (62; 16). See the Clinical manifestations section for further discussion.

Life expectancy may not be affected. However, though the long-term functional outcome and survival have improved, the overall efficacy of antimyoclonic drugs remains unsatisfactory (16).

One study showed that EPM1 progresses only over a limited period and stabilizes thereafter (76). However, in a multicenter study of the circumstances of death amongst 19 patients with EPM1, six patients died of sudden unexpected death in epilepsy, four patients died of a stroke, drowning, complications of chronic alcoholism, and Wernicke encephalopathy, two committed suicide, and one died in a car accident (54). The authors concluded that although the prognosis of EPM1 has improved, there are still severe forms and high risk of early death, including sudden unexpected death in epilepsy (54).

Earlier age at onset for EPM1 and longer disease duration are associated with more severe action myoclonus, lower performance IQ, increased motor threshold, and prolonged silent period (42).

Canafoglia and associates explored the course of EPM1 and identified the risk factors for severity detectable near disease onset (12). They retrospectively evaluated 59 Italian patients carrying the CSTB expansion mutation and coded the information every 5 years after the disease onset to describe the cumulative time-dependent probability of reaching disabling myoclonus, relevant cognitive impairment, and inability to work, and evaluated the influence of early factors using the log-rank test. The risk factors were included in a Cox multivariate proportional hazards regression model. Disabling myoclonus occurred an average of 32 years after disease onset, whereas cognitive impairment occurred a little later. Age at onset of fewer than 12 years, the severity of myoclonus at the time of first assessment, and seizure persistence more than 10 years after onset affected the timing of disabling myoclonus and cognitive decline. Most patients became unable to work years before the appearance of disabling myoclonus or cognitive decline. The authors concluded that a younger age at onset, early severe myoclonus, and seizure persistence are predictors of a more severe outcome. All of these factors may be genetically determined, but the greater hyperexcitability underlying more severe seizures and myoclonus at onset may also play a role by increasing cell damage due to reduced cystatin B activity (12).

Clinical vignette

An 18-year-old girl had EPM1 that began at 12 years of age with action myoclonus and generalized tonic-clonic seizures. Despite major antimyoclonic therapy, including valproate, phenobarbital, benzodiazepines, and piracetam at 27 g/day, she was markedly handicapped by major myoclonic jerks elicited by action, intention of action, or even any cutaneous stimuli. There was also a pseudocerebellar syndrome with the finger-to-nose maneuver and marked photosensitivity (110).

Progressive myoclonic epilepsy type 1 (EPM1) disease: clinical manifestations

This 18-year-old girl has progressive myoclonic epilepsy type 1 (EPM1) disease that began at 12 years of age with action myoclonus and generalized tonic-clonic seizures. Despite major antimyoclonic therapy, including valproate,...

Biological basis

Etiology and pathogenesis

Progressive myoclonic epilepsy type 1 (EPM1) is inherited as an autosomal recessive trait.

Mutations of the cystatin B (CSTB) gene (formal name = EPM1) are responsible for the disease. The CSTB gene has been mapped to chromosome 21q22.3 and encodes a protein that attains several biological roles from functioning as a lysosomal cysteine protease inhibitor to regulating glial activation, oxidative stress, serotonergic neurotransmission, and hyperexcitability (see Table 1) (69; 68; 65; 67; 70; 39; 103; 71; 27; 45; 46).

Linkage to chromosome 21q22.3 has been confirmed in families from several different ethnic groups, suggesting that nonallelic genetic heterogeneity is unlikely (71).

Various nonsense, missense, and frameshift mutations leading to a loss-of-function of the protein product of CSTB have been described, for a total of about 19 mutations (105). Although, in about 90% of the worldwide cases and 99% of the Finnish cases, EPM1 is caused by one of those mutations causing an increase in the size of the CSTB gene. One region of the CSTB gene has a particular repeating sequence of 12 DNA building blocks (nucleotides). This sequence is normally repeated two or three times within the gene and is called a dodecamer repeat. The main CSTB mutation in EPM1, even among patients of different ethnic origins, is an expansion of a dodecamer repeat (ie, CCCCGCCCCGCG) in the 5' flanking area of CSTB (64; 63). Most normal alleles contain either two or three repeats, whereas rarer normal alleles that are highly unstable contain between 12 and 17 repeats. Mutant expanded alleles have been reported to contain between 30 and 80 copies and are also highly unstable, particularly via parental transmission. Mutant repeat length and disease phenotype are not correlated. Although the repeat expansion is outside the CSTB transcriptional unit, it results in a marked decrease in CSTB expression, at least in certain cell types in vitro. In a study of 66 patients (33 men and 33 women) with genetically confirmed EPM1 and homozygous for the CSTB expansion mutation, the number of dodecamer repeats in CSTB alleles varied between 38 and 77 (42). On average, the size of the longer expanded alleles of patients was independently associated with motor threshold, but exerted only a modulating effect on age at onset, myoclonus severity, and silent period.

CSTB homozygous knockout mice show some parallels to the phenotype of human EPM1 including myoclonic seizures, development of ataxia, and neuropathological changes associated with cell loss via apoptosis. Loss of CSTB function due to mutations is consistent with the observed neurodegenerative pathology and phenotype, but the functional link to the epileptic phenotype of EPM1 remains largely unknown (63). Although animal models are known to not always fully recapitulate in-human phenotype, detailed behavioral studies have revealed additional symptoms, including hyperactivity, reduced startle response, problems in coordination, and lack of inhibition (93), suggesting a more complex phenotype approaching that of humans.

Though the genetic background of EPM1 is a homozygous dodecamer repeat extension mutation in the CSTB gene, mutations occurring in a compound heterozygous form with the expansion mutation have also been reported (20; 59; 13; 04; 10). Heterozygous compound mutations are described to induce a more severe phenotype than that of homozygous dodecameric repetition. However, female patients usually present with less severe symptoms than male patients (04).

Table 1. Etiology of Progressive Myoclonic Epilepsy Type 1 (EPM1)

Gene	Chromosome locus	Protein
CSTB	21q22.3	Cystatin B
OMIM entries	254800 Myoclonic epilepsy of Unverricht and Lundborg
	601145 Cystatin B (CSTB)
*Data sources for this table are from: The Human Genome Organisation, Online Mendelian Inheritance in Man, and Swiss-Prot Protein Knowledgebase.

Another clinical and molecular form of EPM1 localized by homozygosity mapping has been described by Berkovic and colleagues (09). This was in an in-bred Arab family with a clinical pattern compatible with EPM1, but mutations in the CSTB gene were absent. The family was mapped to chromosome 12. A similar Arab family with the gene mapping also to the pericentromeric region of chromosome 12 has also been described by El-Shanti and colleagues (22). Chromosome 12 does not contain genes for any other form of progressive myoclonus epilepsy, nor does it have genes known to be related to cystatin B.

The pathogenesis of EPM1 is still unknown. The increased number of dodecamer repeats in the CSTB gene seems to interfere with the production of the cystatin B protein. Levels of cystatin B in affected individuals are only 5% to 10% of normal, preventing proper inhibition of cathepsin, which levels are significantly increased. It is presumed that with mutations in cystatin B and loss of its inhibition of cysteine proteases, apoptosis proceeds abnormally and neurodegeneration results (103; 105). A cystatin B multiprotein complex may have a specific cerebellar function.

Another hypothesis is that in at least a subset of patients with EPM1, cystatin B protein may aggregate in the cell (14). Protein aggregation can be secondary to external insults, aging, or inherited forms of neurodegenerative diseases. Protein aggregates lead to increased production of the reactive oxygen species, dysfunction of the ubiquitin/proteasome system, mitochondrial dysfunction, and dysfunctional Ca2+ signaling. Moreover, RNA extracted from the brains of Cstb knockdown mice was analyzed by Joensuu and colleagues using microarray techniques to identify the transcriptomic signature of EPM1 (47). Of note, the upregulation of genes encoding complement proteins (C1qa, C1qb, C1qc, C4b, and C3ar1), major immunohistocompatibility complex class I (MHC-I), b2-microglobulin (B2m), glial fibrillary acid protein (Gfap), chemokines (Cxcl13 and Ccl6), immunoglobulin receptors (Fcgr3 and Fcgr1g), and other immune and defense response genes was found. Hence, early-onset neuroinflammation and the related glial activation was believed to contribute to the pathogenesis of the disease, promoting recurrent seizures and neuronal degeneration (47). Additionally, the CNS’s proinflammatory state is accompanied by peripheral inflammation demonstrated by high chemokines and cytokines serum concentrations (particularly, Cxcl13 has also been proposed as a marker of the disease) (88). Presently, it still sounds difficult to rule out the exact “order of events” in the neuroinflammatory process, although the possibility to identify disease-specific biomarkers (as Cxcl13) will be of undoubted interest (101; 24).

Buzzi and associates provided direct evidence that loss of cortical GABA input leads to a condition of latent hyperexcitability that favors myoclonus and seizures (11). They tested the hypothesis that EPM1 is accompanied by a loss of cortical GABA inhibition in a murine model (the CSTB knockout mouse) and a human case. Cortical GABA signaling has been investigated by measuring VGAT immunohistochemistry (a histological marker of the density of GABA terminals), GABA release from synaptosomes, and paired-pulse stimulation. In CSTB knockout mice, a progressive decrease in neocortex thickness was found and was associated with a prevalent loss of GABA interneurons. A marked reduction in VGAT labeling was found in the cortex of both CSTB knockout mice and a patient with EPM1. This implicates a reduction in GABA synaptic transmission, which was confirmed in the mouse model as a reduction in GABA release from isolated nerve terminals and as loss of electrophysiologically measured GABA inhibition. The alterations in VGAT immunolabeling progressed in time, paralleling the worsening of myoclonus (11).

Danner and associates aimed to characterize the relationship between the excitability and anatomy of the motor cortex and their association with the severity of the clinical symptoms. Seventy genetically verified patients were compared with 40 healthy controls (19). The symptoms were evaluated with the Unified Myoclonus Rating Scale. Navigated transcranial magnetic stimulation (TMS) was applied to characterize the excitability of the primary motor cortex by determining the motor thresholds and cortical silent periods. Also, the induced cortical electric fields were estimated using individual scalp-to-cortex distances measured from MRIs. A cortical thickness analysis was performed to elucidate possible disease-related anatomical alterations. The motor thresholds, cortical electric fields, and silent periods were significantly increased in the patients (P < 0.01). The silent periods correlated with the myoclonus scores (r = 0.48 to r = 0.49, P < 0.001). The scalp-to-cortex distance increased significantly with disease duration (r = 0.56, P < 0.001) and correlated inversely with cortical thickness. The authors concluded that their results may reflect the refractory nature of the myoclonus and indicate a possible reactive cortical inhibitory mechanism to the underlying disease process (19).

Similarly, Julkunen and colleagues studied seven genetically verified patients with EPM1 and six healthy control subjects (49). They utilized transcranial magnetic stimulation to induce cortical responses measured with EEG in order to observe prevailing cortical excitability/inhibition changes, as well as power and coherence of the cortical oscillations in EPM1. Navigated TMS was focused on the left primary motor cortex at the representation area of the right thumb. TMS-EEG responses were measured at 90% of the resting motor threshold intensity in 110 to 150 trials. It was found that P30 waveform following the TMS was significantly (p < 0.05) increased in patients with EPM1, suggesting increased cortico-cortical excitability, whereas the later N100/P180 waveform was significantly (p < 0.05) decreased, indicating reduced inhibition. In the event-related spectral perturbation, alpha, beta, and gamma band oscillations following the TMS were significantly lower in power in the patients with EPM1 compared to controls. In the alpha and beta bands, the intertrial coherence (ITC) representing the degree of synchronization was also decreased in EPM1. These results suggest abnormal reactivity in EPM1, and may indicate impaired cortico-cortical inhibition and attenuation of subsequent cortical circuits or the thalamic or subcortical nuclei (49). The same group of researchers studied the neurophysiological mechanisms behind the impaired thalamocortical system in patients with EPM1 through short-term adaptation of the motor cortex to transcranial magnetic stimulation via repetition suppression phenomenon (48). Their results suggested that neural processing of external stimuli is progressively impaired in EPM1, possibly due to anatomically impaired thalamocortical system or inhibitory tonus preventing sufficient adaptive reactiveness to stimuli (48).

Sensory hyperexcitability in EPM1 as revealed by giant somatosensory evoked potentials (SEP) has been studied (113; 55). In one study of 25 patients with EPM1 compared with 20 controls, SEPs were evaluated by applying median nerve stimuli and the SEP recovery function (SEP-R) using paired stimuli at interstimulus intervals of between 20 and 600 ms (113). The SEPs were considered "giant" if the N20P25 and P25N33 amplitudes exceeded normal mean values by +3SD. It was found that during the paired-stimulus protocol, the SEPs elicited by the second stimulus (S2) were detectable at all interstimulus intervals but consistently suppressed in the 13 patients with giant SEPs, reflecting a significantly delayed SEP-R. Maximal suppression roughly corresponded to the plateau of a broad middle latency (> 100 ms) wave pertaining to the S1 response. The authors concluded that cortical processing dysfunction generating giant SEPs in patients with EPM1 consistently combines with a long-lasting suppression of hyperexcitability that leads to a delayed giant SEP-R without obstructing the response to incoming stimuli. The delayed SEP-R is not due to true inhibition but the suppression of aberrant hyper-synchronization sustaining giant SEPs. A broad middle latency SEP component adds a significantly suppressive effect. This suggests that cortico-subcortical circuitries contribute to both the gigantism and the delayed SEP-R (113). In the other study, SEPs to median nerve stimulation were repeatedly examined in seven genetically diagnosed Japanese patients with a mean interval of 11.9 years (55). The degree of temporal changes in the amplitude of three early cortical components, N20, P25, and N35, to the age was analyzed and compared with that of healthy subjects. It was found that the clinical course of the patients was almost stable during the follow-up period, namely cessation of generalized tonic-clonic seizures and little or no progression of myoclonus. SEP amplitudes of P25 and N35 were enlarged in all patients and were gradually decreased with aging in EPM1 on average. The degree of temporal changes of P25 and N35 in patients was similar or even lower than that of healthy subjects.

Manninen and colleagues performed a translational diffusion-tensor imaging study in patients with EPM1 and cystatin B-deficient mice (79). Diffusion-tensor imaging and tract-based spatial statistics (TBSS) were used to compare fractional anisotropic (FA) results and axial, radial, and mean diffusion among patients with EPM1 (n = 19) and control subjects (n = 18). Ex vivo diffusion-tensor imaging and TBSS were used to compare CSTB-/- mice (n = 9) with wild controls (n = 4). Areas of FA decrease in mice were characterized by means of immunohistochemical analysis and transmission electron microscopy. Student t test statistics were applied to report significant findings (threshold-free cluster enhancement, P < .05). It was found that patients with EPM1 showed significantly (P < .05) reduced FA and increased radial and mean diffusion in all major white matter tracts compared with those of control subjects, shown as global FA decrease along the TBSS skeleton (0.41 +/- 0.03 vs. 0.45 +/- 0.02, respectively; P < 5 x 10(-6)). CSTB-/- mice exhibited significantly reduced FA (P < .05) and antimyelin basic protein staining. Transmission electron microscopy revealed degenerating axons in CSTB-/- mice versus controls (979 axons counted, 51 degenerating axons; 2.09 +/- 0.29 per field vs. 1072 axons counted, 9 degenerating axons; 0.48 +/- 0.19 per field; P = .002). These results indicate that EPM1 is characterized by widespread alterations in subcortical white matter, the thalamocortical system, and the cerebellum, which result in axonal degeneration and white matter loss. Motor disturbances and other symptoms in patients with EPM1 involve not only the cortical system but also the thalamocortical system and cerebellum (79).

Another study estimated the appropriateness of generalized partial directed coherence (GPDC) in detecting myoclonus-related EEG-EMG connectivity pattern and the information flow between sensorimotor cortex and muscles in patients with typical cortical myoclonus due to EPM1 (91). In 13 patients with cortical myoclonus, the authors analyzed the EEG and EMG signals recorded during simple voluntary motor activities using GPDC, a frequency domain linear index of connectivity estimated from a multivariate autoregressive model. The results were compared with those obtained in 12 healthy controls. The GPDC revealed a peculiar pattern characterizing patients with cortical myoclonus with respect to healthy subjects. Patients consistently had a significantly more robust outflow toward activated muscle originating from cortical areas exceeding the motor one. Moreover, they also had a more robust EMG outflow directed toward a wider cortical area contralateral to the activated hand and sometimes also toward the ipsilateral central region. These results indicate the recruitment of extensive cortical network in afferent and efferent EEG-EMG relationships. Given that robust cortical outflow can be considered as the pathogenic mechanism sustaining myoclonus, the perturbation from the EMG outflow could lead to the involvement of the large cortical area implied in sensorimotor integration and become capable of generating and maintaining the jerk recurrence.

Kononen and associates aimed to elucidate possible alterations in cortical activation related to motor performance in EPM1 (56). Fifteen patients with EPM1 and 15 healthy volunteers matched for age and sex underwent motor functional MRI. Group differences in activations were evaluated in the primary and supplementary motor cortices and sensory cortical areas. Furthermore, in patients with EPM1, the quantitative fMRI parameters were correlated with the severity of the motor symptoms. It was found that the patients with EPM1 exhibited decreased activation in the left inferior frontal junction during right hand voluntary motor task when compared with controls. In the quantitative analysis, patients with EPM1 had significantly weaker activation than controls in the hand knob and supplementary motor areas. The volume of activation in M1 decreased with age and duration of disease in the patient group, whereas the volume increased with age in controls. Negative correlations were observed between fMRI parameters of supplementary motor areas and disease duration or age in patients but not in controls. The authors concluded that the weaker motor fMRI activation observed in patients with EPM1 parallels previous neurophysiological findings and correlates with the motor symptoms of the disease. Thus, the observed decrease in inferior frontal junction activation in patients with EPM1 may be associated with the difficulties in initiation or termination of motor execution, which is a typical clinical symptom in EPM1 (56).

Rossi Sebastiano and colleagues investigated whether the structural cortical changes observed in patients with EPM1 did correlate with the functional reorganization of the motor cortex (100). Seven adult patients with EPM1 and seven age-matched controls underwent transcranial magnetic stimulation-based cortical mapping of the motor hand areas combined with functional magnetic resonance imaging and cortical thickness analyses. Vertex-wise cortical thickness analysis revealed thinning in the precentral gyrus bilaterally and in the left supplementary motor area. Eventually, the motor-evoked potentials centers of gravity of the abductor brevis pollicis muscles and the peak of activation at functional magnetic resonance imaging were shifted toward the posterior regions, suggesting a reshaping of the sensorimotor areas. In conclusion, a transcranial magnetic stimulation-based approach to brain mapping may be used to identify the cortical reorganization of the cortical motor system possibly deriving from both plastic changes and the same pathophysiological process underlying the disease (100).

Pathology. Vacuoles may be present in eccrine sweat glands.

Unverricht-Lundborg disease (photomicrograph)

Semithin epoxy resin section from a skin biopsy of a patient with progressive myoclonic epilepsy type 1 (EPM1). Marked vacuolation involves eccrine secretory cells but spares myoepithelial cells (arrows) and a nearby eccrine du...

Their contents have not been identified. They may not be exclusive manifestations of EPM1 and have occasionally been found in other, clearly unrelated, disorders (17).

The pathological abnormalities of EPM1 first described by Haltia and colleagues involved mainly the cerebellum with Purkinje cell loss (36). There has been a great deal of variation in the description of the pathology, and many of the additional changes described most likely represented artifacts (34).

Differential diagnosis

Progressive myoclonic epilepsy type 1 (EPM1) may be underdiagnosed in patients with severe myoclonus epilepsy (21).

The most common forms of progressive myoclonus epilepsy are EPM1, Lafora disease, sialidosis, neuronal ceroid lipofuscinoses, and myoclonus epilepsy with ragged-red fibers (MERRF).

A more recently described syndrome of myoclonus epilepsy and ataxia due to recurrent KCNC1 p.R320H potassium channel mutation resembles EPM1, despite genetic and biological differences (89). Symptoms begin at between 3 and 15 years of age, with progressively severe myoclonus and rare tonic-clonic seizures. Ataxia presents early, but quickly becomes overshadowed by myoclonus. Mild cognitive decline occurs in half. Electroencephalogram shows generalized spike and polyspike wave discharges, with documented photosensitivity in most. Polygraphic EEG-electromyographic studies demonstrated a cortical origin for myoclonus and striking coactivation of agonist and antagonist muscles. Magnetic resonance imaging reveals symmetrical cerebellar atrophy, which appears progressive, and a prominent corpus callosum. Transient clinical improvement with fever is often noted in most patients. Myoclonus epilepsy and ataxia due to potassium channel mutation causing loss of the channel functioning (ie, reduced or absent potassium currents) have a relatively homogeneous presentation, resembling EPM1, despite the genetic and biological basis being quite different (89; 115).

Lafora body disease, a form of progressive myoclonus epilepsy starting between the ages of 11 and 18 and progressing relentlessly to dementia with an average age at death of 24 years, must be considered. Sialidosis, or cherry-red spot myoclonus syndrome, is a form of progressive myoclonus epilepsy not associated with mental deterioration. The eye findings are characteristic, and oligosaccharides are found in the urine. The juvenile form of neuronal ceroid lipofuscinosis, Spielmeyer-Vogt-Sjögren or Batten disease, begins between the ages of 5 and 8 years of age with progressive visual impairment, followed in the early teens by myoclonus, other types of seizure, deterioration of cognitive skills and speech, ataxia or clumsiness, and Parkinsonian-like extrapyramidal symptoms. As the disease progresses, myoclonus and other symptoms rapidly deteriorate and the patient loses all skills of communication, mobility, and self-help. The CLN3 gene in chromosome 16 accounts for 73% of all cases of juvenile neuronal ceroid lipofuscinosis. The diagnosis of neuronal ceroid lipofuscinosis is based on clinical findings, electron microscopy of tissue biopsy, and, in some instances, an assay of enzyme activity and molecular genetic testing.

Myoclonus epilepsy with ragged-red fibers often presents in this age group. There may be evidence for peripheral nerve dysfunction, and muscle involvement may be demonstrated by the finding of ragged-red fibers on biopsy. This maternally inherited disorder may be associated with features of MELAS syndrome. Short stature, optic atrophy, and bilateral lipomas may be found. Uncommon forms of progressive myoclonus epilepsy include juvenile neuroaxonal dystrophy, the neuronopathic form of Gaucher disease, atypical inclusion-body disease, and renal failure myoclonus syndrome (05).

Diagnostic workup

The diagnosis of EPM1 is made based on family history, age at onset, geographical and ethnic context, and on the typical features of myoclonus and epilepsy, in the absence of severe cognitive and sensory deficits (29).

Exclusion of other forms of progressive myoclonus epilepsy in the presence of the characteristic clinical features makes the diagnosis possible. EPM1 should be suspected when there are significant periods of worsening and improvement as well as a substantially beneficial effect of alcohol on myoclonus.

Detection of CSTB gene mutations confirms the clinical suspicion of EPM1. Genetic testing for heterozygotes and even prenatal diagnosis are both possible (66). All other tests are not specific for this disease. The changes of mitochondrial disease or of Lafora body disease are absent from muscle and skin biopsy material in EPM1. Vacuoles in eccrine sweat glands may be present, but there is no storage material. Biochemical abnormalities have not been demonstrated.

The interictal EEG is initially normal but abnormalities always appear as the disease progresses. Myoclonic jerks may or may not be associated with EEG changes.

Progressive myoclonic epilepsy type 1 (EPM1) - action myoclonus

(A) On execution of a requested movement (“raise you right hand toward the head”) intense repeated myoclonias maximal in the agonist arm muscles are followed by atonias of long (more than 500 ms) duration, with or without multi...
Unverricht-Lundborg disease (ictal EEG)

Frequent spontaneous jerks are seen following generalized bursts of spikes (red arrows), but these can also occur without EEG changes (black arrow). A generalized burst of polyspikes (blue arrow) during 0.5 Hz intermittent photic ...
Unverricht-Lundborg disease: myoclonic jerks without discernible EEG changes

(Ictal EEG) During clinical myoclonic jerks of arms and legs (see EMG channels), there were no discernible EEG changes. The lower parts of the figure represent simultaneously recorded bilateral surface EMG from several proximal to...
Unverricht-Lundborg disease: photosensitivity

Clinically generalized myoclonus and associated EEG photosensitivity. (Courtesy of Dr. R Kalviainen. From:Kalviainen R, Mervaala E. Unverricht-Lundborg disease (EPM1). In: Panayiotopoulos CP, editor. Atlas of epilepsies. London: S...

Photosensitivity is common. In a long-term EEG evaluation of patients with EPM1, alpha activity was normal in 68% of patients at the beginning of the disease and kept stable over the years (26). Generalized spike-wave discharges were present in 92% of patients at the onset of the disease and gradually disappeared during the follow-up with a significant difference (p< 0.001) after the 15th year of the disease. Photoparoxysmal responses were present in 88% of patients at the disease onset and gradually disappeared with a significant difference (p< 0.001) after the 10th year of the disease. A gradual reduction of generalized spike-wave discharges and a progressive disappearance of physiological sleep patterns were observed in sleep EEGs. Gargouri-Berrechid and associates studied the long-term evolution of EEG in EPM1 and concluded that the progressive disappearance of EEG abnormalities is rather due to antiepileptic treatment than a gradual spontaneous tendency to decrease over time (28).

Specific neurophysiological testing as per any other cortical myoclonus is abnormal (90; 109; 35). Cortical neurophysiology reveals a transient wave preceding myoclonus on EEG jerk-locked back-averaging, enlarged somatosensory evoked potentials, and positive long-loop C-reflexes at rest.

Brain MRI is normal at the initial stages of disease onset. An MRI morphometric analysis of 10 patients demonstrated a significant loss of bulk of the basis pontis, medulla, and cerebellar hemispheres compared to controls (81). T1-weighted, 3D images analyzed with voxel-based morphometry revealed atrophy in the bilateral primary, premotor, and supplementary motor cortex (58). The thalamus and precuneus were also bilaterally affected, but no infratentorial changes were detected in the group analysis (58). Patients with EPM1 have significantly more T2-weighted high-intensity signals on MRI than control subjects due to the increased prevalence of these signals in the basal ganglia (57). Koskenkorva and associates evaluated possible changes in CTH of patients with EPM1 compared with healthy controls and correlated those changes with clinical parameters (60). Fifty-three genetically verified patients with EPM1 and 70 healthy volunteers matched for age and sex underwent 1.5T MR imaging. T1-weighted 3D images were analyzed with CTH analysis to detect alterations. The patients were clinically evaluated for myoclonus severity by using the UMRS. Higher UMRS scores indicate more severe myoclonus. CTH analysis revealed significant thinning of the sensorimotor and visual and auditory cortices of patients with EPM1 compared with healthy controls. CTH was reduced with increasing age in both groups, but in the patients the changes were confined specifically to the aforementioned areas whereas in controls the changes were more diffuse. Duration of the disease and the severity of myoclonus correlated negatively with CTH. The authors concluded that cortical thinning in the sensorimotor areas in EPM1 correlated significantly with the degree of the severity of the myoclonus and is most likely related to the widespread stimulus sensitivity in EPM1.

Nigri and associates assessed the structural and functional involvement of the cerebellum in 13 patients with mild to moderate myoclonus of EPM1 (85). They used voxel-based morphometry and spatially unbiased infratentorial template analyses of structural magnetic resonance imaging scans and functional MRI scans during block and event-related go/no-go motor tasks. The results were compared with those obtained in 12 age-matched healthy controls and in 12 patients with hereditary spinocerebellar ataxia. Structural analyses revealed different patterns of atrophic changes in the patients with EPM1 and those with hereditary spinocerebellar ataxia: in the former, they involved both cerebrum and cerebellum, but in the latter, only the cerebellum. During fMRI, block and event-related go/no-go tasks similarly activated the cerebellum and cerebrum in the patients with EPM1 and healthy controls, whereas both tasks revealed much less cerebellar activation in the patients with hereditary spinocerebellar ataxia than in the other two groups. Volumetric evaluation of the patients with EPM1 showed that the cerebellum seemed to be marginally involved in a widespread atrophic process, and fMRI showed that it was not functionally impaired during motor tasks (85).

Magnetic resonance spectroscopy has been used to reveal altered metabolite peak ratios in certain brain areas, such as the pons and dentate nucleus (81). However, extensive cerebral metabolic changes have seldom been investigated over time. The first MRS study of the supratentorial brain was conducted by Hyppönen and colleagues (43). In this work, patients with genetically confirmed EPM1 showed brain metabolic changes in the lactate-to-creatine (Lac/Cr) and N-acetyl-aspartate-to-creatine (NAA/Cr) ratios. Specifically, NAA/Cr decreased in the insular cortex and basal ganglia with a left-to-right hemisphere predominance, whilst Lac/Cr increased in the thalamus, the insula, white and grey matter of the occipital lobe, and white matter of the splenium. Conversely, no changes in the choline-to-creatine ratios were identified. Similar changes in the thalamus and basal ganglia have also been described in patients with juvenile myoclonic epilepsy, giving hints on the possible generation of action-activated myoclonus. Finally, the Lac/Cr ratio was primarily associated with the performance in neuropsychological tests, with the increase in Lac/Cr inversely related to results at cognitive tests.

Management

This includes prophylactic drug treatment, rehabilitation, and psychosocial support. Valproate, clonazepam, piracetam, and more recently levetiracetam and perampanel are the main antiepileptic agents (18). Zonisamide may also be effective in some cases (38; 44). Generalized tonic-clonic convulsions are relatively easily controlled but the myoclonus has usually been the limiting factor. Unlike most forms of epilepsy, progressive myoclonus epilepsy is best treated by polytherapy (87).

An important aspect of management is to avoid the use of contraindicated antiepileptic drugs such as phenytoin, carbamazepine, gabapentin, or vigabatrin (31). Lamotrigine is also contraindicated. A study found dose-related exacerbation of myoclonus, putative late-onset aggravation, or lack of improvement in five patients treated with adjunctive lamotrigine (29). Because of a promyoclonic effect in focal epilepsies (41), pregabalin is also probably contraindicated in EPM1. Removal of phenytoin may lead to striking improvement and a return of the ability to walk (23).

Magaudda and colleagues studied the efficacy of levetiracetam in 13 patients with EPM1 about seizure frequency and myoclonus by using a simplified myoclonus rating score and comparing the patients' status before levetiracetam and at the last follow-up (77). Levetiracetam was given at 2000 to 4000 mg/day for 0.5 to 26 months (mean, 13.8 months). One patient stopped levetiracetam within 2 weeks because of side effects and lack of efficacy. None of the other 12 patients reported side effects. The average myoclonus score significantly changed from 3.1 to 2.4 (p = 0.01), but only eight patients had a measurable improvement. The best effects were noted in the younger patients. In patients previously treated with high-dose piracetam, discontinuation of piracetam was not always well tolerated, and a combination of piracetam at lower doses and levetiracetam appeared to be a practical solution. The authors concluded that levetiracetam should probably be considered as a major treatment option early in the course of EPM1 (77). Similarly, Papacostas and colleagues reported three patients with genetically confirmed EPM1 who were treated with levetiracetam as adjunctive therapy for their myoclonus (92). All cases responded with a decrease of their myoclonus and improvement of their quality of life. Two were able to return to or continue their employment. Patients tolerated the drug well without reported side effects.

Italiano and associates carried out a pilot, open-label trial of add-on zonisamide in 12 patients with EPM1 (44). Oral zonisamide was gradually titrated until the target dose of 6 mg/Kg per day. Unified Myoclonus Rating Scale was obtained in each subject before and after zonisamide add-on. A significant reduction of myoclonus severity was reached after zonisamide introduction. Two patients withdrew due to adverse effects.

In a retrospective study of 20 patients with EPM1 at Helsinki University Hospital, the majority of the patients had severe functional disabilities (98). In the year preceding the last hospital visit, all patients were receiving polytherapy, and 14 patients had been free of tonic-clonic seizures. During follow-up, improvement in myoclonia had been recorded for the majority of patients with either add-on piracetam, topiramate, or levetiracetam, but valproate was still in use by all patients. Treatment with lamotrigine had been started and retained less often relative to other antiepileptic drugs. Add-on antiepileptic drug treatment was often associated with significant adverse effects.

Brivaracetam, an antiepileptic agent that is chemically related to levetiracetam, has been granted orphan medicinal designation in Europe and the United States for the treatment of symptomatic myoclonus and progressive myoclonic epilepsies (78; 51; 102). Kalviainen and colleagues assessed the results of brivaracetam in two randomized, double-blind, placebo-controlled studies of EPM1 (50). The effect of brivaracetam on action myoclonus was not statistically significant. However, (1) action myoclonus score showed wide intrapatient variability and may not have been the optimal tool to measure the severity of myoclonus in EPM1, and (2) both studies had very high completion rates (95.3% overall) and a high percentage of patients (88.7% overall) entered long-term follow-up; both likely to be influenced by good tolerability. Thus, the authors concluded that these studies demonstrate the feasibility of rigorous trials in progressive myoclonic epilepsy (50). Patients completing these studies and expected to benefit from brivaracetam treatment were then eligible for the long-term open-label extension study (N01125; NCT00175916) (06). Ninety-four patients with EPM1 (11.0% of the entire cohort) were enrolled into this phase 3, single-arm, open-label extension trial with the primary objective to evaluate long-term safety and tolerability of adjunctive brivaracetam (mean, 100 mg/day in the progressive myoclonic epilepsy type 1 subgroup but up to 200 mg/day). Maintenance of efficacy over the time was a secondary endpoint. As a result, brivaracetam was overall well-tolerated with treatment-emergent adverse events reported by 84.4% of all patients and is primarily related to the CNS, particularly headache and somnolence in the EPM1 subgroup.

In a study of 12 patients with this disease, with perampanel, 10 patients had a clear clinical response of myoclonus, and five were able to reduce concomitant therapy (18). Improvement was noted sometimes as soon as with 2 mg/day. Epileptic seizures stopped on perampanel in the six patients who still had experienced generalized tonic-clonic or myoclonic seizures (100%). Some abatement of efficacy on myoclonus was seen in two patients who still retained some benefit. Weight gain was reported in six patients. Psychological and behavioral side-effects were observed in six patients and led to the withdrawal of perampanel in three cases and dose reduction in three, with abatement of the problems. The authors concluded that: (1) perampanel may show marked efficacy even in severe cases, particularly against myoclonus, but also against seizures; (2) perampanel should be tried in patients with EPM1 whose seizures are not satisfactorily controlled; and (3) its use is limited because of psychological and behavioral side effects, with higher doses of approximately 6 mg/day or greater likely risk factors (18). A systematic review explored the outcomes with perampanel in 59 patients with progressive myoclonic epilepsies in two non-randomized interventional studies (Trinka and Lattanzi 2021). Reductions in myoclonic seizures frequency and severity were seen across study types and different etiologies, including Lafora disease and Unverricht–Lundborg disease; reductions in primary generalized tonic-clonic seizures were also often reported. Considering the uncontrolled nature of these studies and different populations and settings, results are reasonably consistent with meaningful responses in 50% to 80% of patients.

Repetitive transcranial magnetic stimulation can be safely used in patients with EPM1, improves action myoclonus, and partially restores deficient cortical inhibition (99). In one study, nine patients with EPM1 underwent two series of 500 stimuli at 0.3 Hz through a round coil twice a day for five consecutive days (99). Clinical and neurophysiological examinations were performed 2 hours before starting the first session and 2 hours after the end of the last session. Eight patients completed the protocol; one discontinued because of a transient increase in spontaneous jerks. The unified myoclonus rating scale indicated a 25% reduction in posttreatment myoclonus, with an action score associated with an increase in the cortical motor threshold and lengthening of the cortical silent period. The decrease in the myoclonus with action scores correlated with the prolongation of cortical silent period.

An etiologically oriented treatment has also been tested: cell-permeable peptide TAT-protein transduction domains (PTD) fused to cystatin as a potential protein therapy of EPM1 is problematic because TAT-PTD-CSTB does not penetrate the cells despite initial evidence of time- and concentration-dependent transduction. Therefore, it cannot be used as a form of replacement of the intracytoplasmic protein missing in EPM1 (03; 96).

As abnormalities of CSTB mRNA are common effects of various mutations in EPM1, Matos and colleagues developed an antisense oligonucleotide in a Portuguese patient with the homozygous c.66G>A CSTB mutation, which activates a cryptic splice site downstream in CSTB intron 1 (83). A specific locked nucleic acid antisense oligonucleotide was designed to complementary target the cryptic donor splice site in intron 1 of the CSTB and redirect splicing. This highlights the feasibility of antisense oligonucleotides therapies and the relevance of personalized treatment for patients (83; 96; 101).

Lastly, as one of the pathological determinants of EPM1 is reactive oxygen species and the oxidative stress, high doses of N-acetyl-cysteine have been tested in some patients showing a marked improvement in seizures, ataxia, and a blockade of symptoms progression (101). This suggests the need to further dissect the specific altered inflammatory pathways in this condition to that to use specific antiinflammatory compounds (96).

In conclusion, the progress in the understanding of the biological bases of EPM1 will provide the bases for precision medicine-based approaches, aiming at targeting the specific mutations and possibly striking the neurodegenerative process underlying this disease. A proof-of-concept CSTB gene replacement study has been performed in Cstb knockout mice by introducing the full-length CSTB driven by the CBh promoter package in adeno-associated virus 9 (AAV9) (33). Therapy was administered at postnatal days 21 and 60, and mice were sacrificed at 2 or 9 months of age. The authors observed an improvement in the expression levels of neuroinflammatory pathways and cerebellar granule cell layer apoptosis, together with improvements in motor functions.

Moreover, the development of new, wearable devices to objectively quantify myoclonus in real life will undoubtedly prove valuable to evaluate treatment effects (95; 106).

Outcomes

The outcome seems related to the severity of the myoclonus, generalized seizures, and ataxia.

There is some disagreement as to whether intelligence remains normal (29) or may deteriorate even when optimal antiepileptic and antimyoclonic treatments are used (62; 16).

Life expectancy may not be affected. However, though the long-term functional outcome and survival have improved, the overall efficacy of antimyoclonic drugs remains unsatisfactory (16).

One study showed that EPM1 progresses only over a limited period and stabilizes thereafter (76). However, in a multicenter study of the circumstances of death amongst 19 patients with EPM1, six patients died of sudden unexpected death in epilepsy, four patients died of stroke, drowning, complications of chronic alcoholism, and Wernicke encephalopathy, two committed suicide, and one died in a car accident (54). The authors concluded that although the prognosis of EPM1 has improved, there are still severe forms and high risk of early death, including sudden unexpected death in epilepsy (54).

Media

References

01: Aikia M, Hypponen J, Mervaala E, Kalviainen R. Cognitive functioning in progressive myoclonus epilepsy type 1 (Unverricht-Lundborg Disease, EPM1). Epilepsy Behavior 2021;122:108157. PMID 34171687
02: Andermann F, Berkovic SF, Carpenter S, Andermann E. The Ramsay Hunt syndrome is no longer a useful diagnostic category. Mov Disord 1989;4:14-7. PMID 2494436
03: Andrade DM, Scherer SW, Minassian BA. Protein therapy for Unverricht-Lundborg disease using cystatin B transduction by TAT-PTD. Is it that simple. Epilepsy Res 2006;72(1):75-9. PMID 16930946
04: Assenza G, Benvenga A, Gennaro E, et al. A novel c132-134del mutation in Unverricht-Lundborg disease and the review of literature of heterozygous compound patients. Epilepsia 2017;58(2):e31-5. PMID 27888502
05: Badhwar A, Berkovic SF, Dowling JP, et al. Action myoclonus-renal failure syndrome: characterization of a unique cerebro-renal disorder. Brain 2004;127(Pt 10):2173-82. PMID 15364701
06: Ben-Menachem E, Baulac M, Hong SB, et al. Safety, tolerability, and efficacy of brivaracetam as adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht-Lundborg disease: an open-label, long-term follow-up trial. Epilepsy Res 2020;170:106526. PMID 33461041
07: Berkovic SF. Progressive myoclonus epilepsies. In: Engel J Jr, Pedley TA, editors. Philadelphia: Lippincott Williams & Wilkins, 2008:2525-35.
08: Berkovic SF, Andermann F, Carpenter S, Wolfe LS. Progressive myoclonus epilepsies: specific causes and diagnosis. N Engl J Med 1986;315(5):296-305. PMID 3088452
09: Berkovic SF, Mazarib A, Walid S, et al. A new clinical and molecular form of Unverricht-Lundborg disease localized by homozygosity mapping. Brain 2005;128:652-8. PMID 15634728
10: Bosak M, Sułek A, Łukasik M, Żak A, Słowik A, Lasek-Bal A. Genetic testing and the phenotype of Polish patients with Unverricht-Lundborg disease (EPM1) - a cohort study. Epilepsy Behav 2020;112:107439. PMID 32920378
11: Buzzi A, Chikhladze M, Falcicchia C, et al. Loss of cortical GABA terminals in Unverricht-Lundborg disease. Neurobiol Dis 2012;47:216-24. PMID 22538221
12: Canafoglia L, Ferlazzo E, Michelucci R, et al. Variable course of Unverricht-Lundborg disease: early prognostic factors. Neurology 2017;89(16):1691-7. PMID 28931642
13: Canafoglia L, Gennaro E, Capovilla G, et al. Electroclinical presentation and genotype-phenotype relationships in patients with Unverricht-Lundborg disease carrying compound heterozygous CSTB point and indel mutations. Epilepsia 2012;53:2120-7. PMID 23205931
14: Ceru S, Rabzelj S, Kopitar-Jerala N, Turk V, Zerovnik E. Protein aggregation as a possible cause for pathology in a subset of familial Unverricht-Lundborg disease. Med Hypotheses 2005;64(5):955-9. PMID 15780491
15: Chan EM, Andrade DM, Franceschetti S, Minassian. Progressive myoclonus epilepsies: EPM1, EPM2A, EPM2B. Adv Neurol 2005;95:47-57. PMID 15508913
16: Chew NK, Mir P, Edwards MJ, et al. The natural history of Unverricht-Lundborg disease: a report of eight genetically proven cases. Mov Disord 2008;23(1):107-13. PMID 17994572
17: Cochius J, Carpenter S, Andermann E, et al. Sweat gland vacuoles in Unverricht-Lundborg disease: a clue to diagnosis. Neurology 1994;44(12):2372-5. PMID 7991128
18: Crespel A, Gelisse P, Tang NP, Genton P. Perampanel in 12 patients with Unverricht-Lundborg disease. Epilepsia 2017;58(4):543-7. PMID 28166365
19: Danner N, Julkunen P, Hypponen J, et al. Alterations of motor cortical excitability and anatomy in Unverricht-Lundborg disease. Mov Disord 2013;28(13):1860-7. PMID 23925991
20: Danner N, Julkunen P, Kononen M, et al. Primary motor cortex alterations in a compound heterozygous form of Unverricht-Lundborg disease (EPM1). Seizure 2011;20(1):65-71. PMID 21075014
21: de Haan GJ, Halley DJ, Doelman JC, et al. Unverricht-Lundborg disease: underdiagnosed in the Netherlands. Epilepsia 2004;45(9):1061-3. PMID 15329070
22: El-Shanti H, Daoud A, Sadoon AA, et al. A distinct autosomal recessive ataxia maps to chromosome 12 in an inbred family from Jordan. Brain Dev 2006;28(6):353-7. PMID 16376507
23: Eldridge R, Iivanainen M, Stern R, Koerber T, Wilder BJ. "Baltic" myoclonus epilepsy: hereditary disorder of childhood made worse by phenytoin. Lancet 1983;2(8354):838-42. PMID 6137660
24: Espinós C, Galindo MI, García-Gimeno MA, et al. Oxidative stress, a crossroad between rare diseases and neurodegeneration. Antioxidants (Basel) 2020;9(4):313. PMID 32326494
25: Ferlazzo E, Gagliano A, Calarese T, et al. Neuropsychological findings in patients with Unverricht-Lundborg disease. Epilepsy Behav 2009;14(3):545-9. PMID 19185615
26: Ferlazzo E, Magaudda A, Striano P, Vi-Hong N, Serra S, Genton P. Long-term evolution of EEG in Unverricht-Lundborg disease. Epilepsy Res 2007;73:219-27. PMID 17158032
27: Franceschetti S, Sancini G, Buzzi A, et al. A pathogenetic hypothesis of Unverricht-Lundborg disease onset and progression. Neurobiol Dis 2007;25(3):675-85. PMID 17188503
28: Gargouri-Berrechid A, Nasri A, Kacem I, et al. Long-term evolution of EEG in Unverricht-Lundborg disease. Neurophysiol Clin 2016;46(2):119-24. PMID 27157382
29: Genton P. Unverricht-Lundborg disease (PME1). Rev Neurol (Paris) 2006;162(8-9):819-26. PMID 17028542
30: Genton P, Gelisse P, Crespel A. Lack of efficacy and potential aggravation of myoclonus with lamotrigine in Unverricht-Lundborg disease. Epilepsia 2006;47(12):2083-5. PMID 17201707
31: Genton P, Malafosse A, Moulard B, et al. Progressive myoclonus epilepsies. In: Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P, editors. Epileptic Syndromes in Infancy, Childhood and Adolescence. Montrouge, France: John Libbey Eurotext, 2005:441-65.
32: Giovagnoli AR, Canafoglia L, Reati F, Raviglione F, Franceschetti S. The neuropsychological pattern of Unverricht-Lundborg disease. Epilepsy Res 2009;84(2-3):217-23. PMID 19261441
33: Gumusgoz E, Kasiri S, Verma M, et al. CSTB gene replacement improves neuroinflammation, neurodegeneration and ataxia in murine type 1 progressive myoclonus epilepsy. Gene Ther 2024;31(5-6):234-41.** PMID 38135787
34: Habib M, Roger J, Khalil R, et al. Progressive degenerative myoclonic epilepsy. Systematized olivo-cerebellar lesions. Rev Neurol (Paris) 1985;141(4):274-88. PMID 3925524
35: Hainque E, Blancher A, Mesnage V, et al. A clinical and neurophysiological motor signature of Unverricht-Lundborg disease. Rev Neurol (Paris) 2018;174(1-2):56-65. PMID 28688606
36: Haltia M, Kristenson K, Sourander P. Neuropathological studies in three Scandinavian cases of progressive myoclonus epilepsy. Acta Neurol Scand 1969;45:63-77. PMID 4979532
37: Harding AE. Ramsay Hunt syndrome, Unverricht-Lundborg disease, or what. Mov Disord 1989;4(1):18-9. PMID 2494437
38: Henry TR, Leppik IE, Gumnit RJ, Jacobs M. Progressive myoclonus epilepsy treated with zonisamide. Neurology 1988;38(6):928-31. PMID 3130586
39: Horiuchi H, Osawa M, Furutani R, et al. Polymerase chain reaction-based analysis using deaminated DNA of dodecamer expansions in CSTB, associated with Unverricht-Lundborg myoclonus epilepsy. Genet Test 2005;9(4):328-33. PMID 16379547
40: Hosny H, El Tamawy M, Gouider R, et al. Clinical and molecular characterization of Unverricht-Lundborg disease among Egyptian patients. 2021;176:106746. PMID 34474241
41: Huppertz HJ, Feuerstein TJ, Schulze-Bonhage A. Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia 2001;42(6):790-2. PMID 11422338
42: Hypponen J, Aikia M, Joensuu T, et al. Refining the phenotype of Unverricht-Lundborg disease (EPM1): a population-wide Finnish study. Neurology 2015;84(15):1529-36. PMID 25770194
43: Hypponen J, Paanila V, Äikiä M, et al. Progressive myoclonic epilepsy type 1 (EPM1) patients present with abnormal 1H MRS brain metabolic profiles associated with cognitive function. Neuroimage Clin 2023:39:103459. PMID 37541097
44: Italiano D, Pezzella M, Coppola A, et al. A pilot open-label trial of zonisamide in Unverricht-Lundborg disease. Mov Disord 2011;26(2):341-3. PMID 20939070
45: Joensuu T, Kuronen M, Alakurtti K, et al. Cystatin B: mutation detection, alternative splicing and expression in progressive myoclonus epilepsy of Unverricht-Lundborg type (EPM1) patients. Eur J Hum Genet 2007;15(2):185-93. PMID 17003839
46: Joensuu T, Lehesjoki AE, Kopra O. Molecular background of EPM1-Unverricht-Lundborg disease. Epilepsia 2008;49(4):557-63. PMID 18028412
47: Joensuu T, Tegelberg S, Reinmaa E, et al. Gene expression alterations in the cerebellum and granule neurons of Cstb(-/-) mouse are associated with early synaptic changes and inflammation. PLoS One 2014;9(2):e89321. PMID 24586687
48: Julkunen P, Lofberg O, Kallioniemi E, Hypponen J, Kalviainen R, Mervaala E. Abnormal motor cortical adaptation to external stimulus in Unverricht-Lundborg disease (progressive myoclonus type 1, EPM1). J Neurophysiol 2018;120(2):617-23. PMID 29742025
49: Julkunen P, Saisanen L, Kononen M, Vanninen R, Kalviainen R, Mervaala E. TMS-EEG reveals impaired intracortical interactions and coherence in Unverricht-Lundborg type progressive myoclonus epilepsy (EPM1). Epilepsy Res 2013;106(1-2):103-12. PMID 23642573
50: Kalviainen R, Genton P, Andermann E, et al. Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies. Epilepsia 2016;57(2):210-21. PMID 26666500
51: Kalviainen R, Khyuppenen J, Koskenkorva P, Eriksson K, Vanninen R, Mervaala E. Clinical picture of EPM1-Unverricht-Lundborg disease. Epilepsia 2008;49(4):549-56. PMID 18325013
52: Kalviainen R, Mervaala E. Unverricht-Lundborg disease (EPM1). In: Panayiotopoulos CP, editor. Atlas of epilepsies. London: Springer, 2010:1225-30.
53: Kecmanovic M, Ristic AJ, Ercegovac M, et al. A shared haplotype indicates a founder event in Unverricht-Lundborg disease patients from Serbia. Int J Neurosci 2014;124(2):102-9. PMID 23883076
54: Khiari HM, Franceschetti S, Jovic N, Mrabet A, Genton P. Death in Unverricht-Lundborg disease. Neurol Sci 2009;30:315-8. PMID 19499178
55: Kobayashi K, Hitomi T, Matsumoto R, et al. Long-term follow-up of cortical hyperexcitability in Japanese Unverricht-Lundborg disease. Seizure 2014;23(9):746-50. PMID 25023721
56: Kononen M, Danner N, Koskenkorva P, et al. Reduced cortical activation in inferior frontal junction in Unverricht-Lundborg disease (EPM1) - A motor fMRI study. Epilepsy Res 2015;111:78-84. PMID 25769376
57: Korja M, Ferlazzo E, Soilu-Hanninen M, et al. T2-weighted high-intensity signals in the basal ganglia as an interesting image finding in Unverricht-Lundborg disease. Epilepsy Res 2010;88(1):87-91. PMID 19896804
58: Koskenkorva P, Khyuppenen J, Niskanen E, et al. Motor cortex and thalamic atrophy in Unverricht-Lundborg disease: voxel-based morphometric study. Neurology 2009;73(8):606-11. PMID 19704079
59: Koskenkorva P, Hypponen J, Aikia M, et al. Severer phenotype in Unverricht-Lundborg disease (EPM1) patients compound heterozygous for the dodecamer repeat expansion and the c.202C>T mutation in the CSTB gene. Neurodegener Dis 2011;8:515-522. PMID 21757863
60: Koskenkorva P, Niskanen E, Hypponen J, et al. Sensorimotor, visual, and auditory cortical atrophy in Unverricht-Lundborg disease mapped with cortical thickness analysis. AJNR Am J Neuroradiol 2012;33:878-83. PMID 22268086
61: Koskiniemi M. Psychological findings in progressive myoclonus epilepsy without Lafora bodies. Epilepsia 1974;15:537-45. PMID 4279170
62: Koskiniemi M. Baltic myoclonus. In: Fahn S, Marsden CD, Van Woert M, editors. Myoclonus: Advances in Neurology. Vol. 43. New York: Raven, 1986:57-64.
63: Lalioti MD, Antonarakis SE, Scott HS. The epilepsy, the protease inhibitor and the dodecamer progressive myoclonus epilepsy, cystatin b and a 12-mer repeat expansion. Cytogenet Genome Res 2003;100:213-23. PMID 14526183
64: Lalioti MD, Scott HS, Buresi C, et al. Dodecamer repeat expansion in cystatin B gene in progressive myoclonus epilepsy. Nature 1997;386:847-51. PMID 9126745
65: Lehesjoki AE, Eldridge R, Eldridge J, Wilder BJ, de la Chapelle A. Progressive myoclonus epilepsy of Unverricht-Lundborg type: a clinical and molecular genetic study of a family from the United States with four affected sibs. Neurology 1993a;43(11):2384-6. PMID 8232963
66: Lehesjoki AE, Kalviainen R. Unverricht-Lundborg disease. In: Gene Reviews at GeneTests: Medical Genetics Information Resource (database online).Copyright, University of Washington, Seattle. 1997-2010. Available at:GeneReviews. Accessed February 2020.
67: Lehesjoki AE, Koskiniemi M, Norio R, et al. Localization of the EPM1 gene for progressive myoclonus epilepsy on chromosome 21: linkage disequilibrium allows high resolution mapping. Hum Mol Genet 1993b;2(8):1229-34. PMID 8104628
68: Lehesjoki AE, Koskiniemi M, Pandolfo M, et al. Linkage studies in progressive myoclonus epilepsy: Unverricht-Lundborg and Lafora's diseases. Neurology 1992;42(8):1545-50. PMID 1641151
69: Lehesjoki AE, Koskiniemi M, Sistonen P, Miao J, Hastbacka J. Localization of a gene for progressive myoclonus epilepsy to chromosome 21q22. Proc Natl Acad Sci U S A 1991;88(9):3696-9. PMID 1673790
70: Lehesjoki AE, Tassinari CA, Avanzini G, et al. PME of Unverricht-Lundborg type in the Mediterranean region: linkage and linkage disequilibrium confirm the assignment to the EPM1 locus. Hum Genet 1994;93(6):668-74. PMID 8005591
71: Lohi H, Chan EM, Scherer SW, Minassian BA. On the road to tractability: the current biochemical understanding of progressive myoclonus epilepsies. Adv Neurol 2006;97:399-415. PMID 16383151
72: Lundborg H. Klinische Studien und Erfahrungen betreffs der familiären Myoklonie und damit verwandten Krankheiten. Svenska Läkarsällskapets Nya Handlingar 1901;Serien III(Delen 3):130.
73: Lundborg H. Die progressive Myoklonus-Epilepsie (Unverricht's Myoklonie). Uppsala: Almqvist und Wiksell's Buchdruckerei-A-G, 1903:1-207.
74: Lundborg H. Der Erbgang der progressiven. Myoklonus-Epilepsie. Z Gesamte Neur Psychatrie 1912;7:353-8.
75: Lundborg H. Race, cultural groups social differentiation: race biological perspectives. Social Forces 1931;9:397-401.
76: Magaudda A, Ferlazzo E, Nguyen VH, Genton P. Unverricht-Lundborg disease, a condition with self-limited progression: long-term follow-up of 20 Patients. Epilepsia 2006:47(5):860-6. PMID 16686650
77: Magaudda A, Gelisse P, Genton P. Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations. Epilepsia 2004;45:678-81. PMID 15144434
78: Malawska B, Kulig K. Brivaracetam UCB. Curr Opin Investig Drugs 2005;6(7):740-6. PMID 16044671
79: Manninen O, Koskenkorva P, Lehtimaki KK, et al. White matter degeneration with Unverricht-Lundborg progressive myoclonus epilepsy: a translational diffusion-tensor imaging study in patients and cystatin B-deficient mice. Radiology 2013;269(1):232-9. PMID 23788720
80: Marsden CD, Harding AE, Obeso JA, Lu CS. Progressive myoclonic ataxia (the Ramsay Hunt syndrome). Arch Neurol 1990;47(10):1121-5. PMID 2121121
81: Mascalchi M, Brugnoli R, Guerrini L, et al. Single-voxel long TE 1H-MR spectroscopy of the normal brainstem and cerebellum. J Magn Reson Imaging 2002;16(5):532-7. PMID 12412029
82: Mascalchi M, Michelucci R, Cosottini M, et al. Brainstem involvement in Unverricht-Lundborg disease (EPM1): An MRI and (1)H MRS study. Neurology 2002;58(11):1686-9. PMID 12058102
83: Matos L, Duarte AJ, Ribeiro D, et al. Correction of a splicing mutation affecting an Unverricht-Lundburg disease patient by antisense therapy. Genes (Basel) 2018;9(9):455. PMID 30208654
84: Nasri A, Zidi S, Kacem I, et al. Major intra-familial variability in Unverricht-Lundborg disease. Epileptic Disord 2022;24(1):163-70. PMID 34787084
85: Nigri A, Visani E, Bertolino N, et al. Cerebellar involvement in patients with mild to moderate myoclonus due to EPM1: structural and functional MRI findings in comparison with healthy controls and ataxic patients. Brain Topogr 2017;30(3):380-9. PMID 27785699
86: Norio R, Koskiniemi M. Progressive myoclonus epilepsy: genetic and nosological aspects with special reference to 107 Finnish patients. Clin Genet 1979;15(5):382-8. PMID 109240
87: Obeso JA, Artieda J, Rothwell JC, Day B, Thompson PM, Marsden CD. The treatment of severe action myoclonus. Brain 1989;112:765-77. PMID 2499399
88: Okuneva O, Li Z, Korber I, et al. Brain inflammation is accompanied by peripheral inflammation in Cstb-/- mice, a model for progressive myoclonus epilepsy. J Neuroinflammation 2016;13(1):298. PMID 27894304
89: Oliver KL, Franceschetti S, Milligan CJ, et al. Myoclonus epilepsy and ataxia due to KCNC1 mutation: analysis of 20 cases and K(+) channel properties. Ann Neurol 2017;81(5):677-89. PMID 28380698
90: Panayiotopoulos CP. A clinical guide to epileptic syndromes and their treatment (Revised 2nd edition). London: Springer, 2010.
91: Panzica F, Canafoglia L, Franceschetti S. EEG-EMG information flow in movement-activated myoclonus in patients with Unverricht-Lundborg disease. Clin Neurophysiol 2014;125(9):1803-8. PMID 24508192
92: Papacostas S, Kkolou E, Papathanasiou E. Levetiracetam in three cases of progressive myoclonus epilepsy. Pharm World Sci 2007;29(3):164-6. PMID 17242859
93: Pollari E, Tegelberg S, Björklund H, Kälviäinen R, Lehesjoki AE, Haapalinna A. In depth behavioral phenotyping unravels complex motor disturbances in Cstb-/- mouse, a model for progressive myoclonus epilepsy type 1. Front Behav Neurosci 2023;17:1325051. PMID 38179183
94: Puschmann A. Unverricht-Lundborg disease-A misnomer. Mov Disord 2009;24(4):629-30. PMID 18512745
95: Rissanen SM, Hypponen J, Silvennoinen K, et al. Wearable monitoring of positive and negative myoclonus in progressive myoclonic epilepsy type 1. Clin Neurophysiol 2021;132(10):2464-72. PMID 34454274
96: Riva A, Guglielmo A, Balagura G, et al. Emerging treatments for progressive myoclonus epilepsies. Expert Rev Neurother 2020;20(4):341-50. PMID 32153206
97: Roger J, Soulayrol R, Hassoun J. La dyssinergie cerebelleuse myoclonique (syndrome de Ramsay Hunt). Rev Neurol (Paris) 1968;119:85-106. PMID 5720761
98: Roivainen R, Karvonen MK, Puumala T. Seizure control in Unverricht-Lundborg disease: a single-centre study. Epileptic Disord 2014;16(2):191-5. PMID 24777117
99: Rossi Sebastino D, Magaudda A, Quartarone A, et al. Effect of repetitive transcranial magnetic stimulation on action myoclonus: a pilot study in patients with EPM1. Epilepsy Behav 2018;80:33-6. PMID 29396360
100: Rossi Sebastiano D, Visani E, Contarino VE, et al. Distortion of the cortical motor map in patients with Unverricht-Lundborg disease: a combined TMS-MRI study. Epilepsy Res 2020;160:106278. PMID 31954920
101: Sanz P, Serratosa JM. Neuroinflammation and progressive myoclonus epilepsies: from basic science to therapeutic opportunities. Expert Rev Mol Med 2020;22:e4. PMID 32938505
102: Schulze-Bonhage A. Brivaracetam for the treatment of epilepsy. Expert Opin Pharmacother 2011;12(12):1959-66. PMID 21682662
103: Shahwan A, Farrell M, Delanty N. Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects. Lancet Neurol 2005;4(4):239-48. PMID 15778103
104: Shakir RA, Khan RA, al-Zuhair AG. Progressive myoclonic ataxia without ragged red fibres: Unverricht-Lundborg disease vs Ramsay Hunt syndrome. Acta Neurol Scand 1992;86(5):470-3. PMID 1336290
105: Singh S, Hamalainen RH. The roles of cystatin B in the brain and pathophysiological mechanisms of progressive myoclonic epilepsy type 1. Cells 2024;13(2):170. PMID 38247861
106: Sinokki A, Säisänen L, Hyppönen J, et al. Detecting negative myoclonus during long-term home measurements using wearables. Clin Neurophysiol 2023:156:166-74. PMID 37952446
107: Sipila JO, Hypponen J, Kyto V, Kalviainen R. Unverricht-Lundborg disease (EPM1) in Finland: a nationwide population-based study. Neurology 2020;95(23):e3123. PMID 32943486
108: Sipila JO, Kalviainen R. Comorbidities in patients with Unverricht-Lundborg disease (EPM1). Acta Neurol Scand 2022;146(5):690-3. PMID 36097839
109: Tassinari AC, Cantalupo G, Rubboli G. Polygraphic recording of epileptic seizures. In: Panayiotopoulos CP, editor. Atlas of epilepsies. London: Springer, 2010:723-40.
110: Thomas P. The Educational Kit On Epilepsies. Volume 2: Idiopathic generalised epilepsies with myoclonic jerks. Oxford: Medicinae, 2007.
111: Trinka E, Lattanzi S, Carpenter K, et al. Exploring the evidence for broad-spectrum effectiveness of perampanel: A systematic review of clinical data in generalised seizures. CNS Drugs 2021;35(8):821-37. PMID 34232492
112: Unverricht H. Die myoclonie. Leipzig: Franz Deuticke, 1891:1-128.
113: Visani E, Canafoglia L, Rossi Sebastiano D, et al. Giant SEPs and SEP-recovery function in Unverricht-Lundborg disease. Clin Neurophysiol 2013;124(5):1013-8. PMID 23276489
114: Vogt H, Baisch T, Mueller-Pfeiffer C, Mothersill IW. Negative myoclonus causes locomotory disability in progressive myoclonus epilepsy type EPM1-Unverricht-Lundborg disease. Epileptic Disord 2023;25(3):297-308. PMID 37536959
115: Zhang Y, Ali SR, Nabbout R, Barcia G, Kaczmarek LK. A KCNC1 mutation in epilepsy of infancy with focal migrating seizures produces functional channels that fail to be regulated by PKC phosphorylation. J Neurophysiol 2021;126(2):532-9. PMID 34232791

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Pasquale Striano MD PhD

Dr. Striano of the University of Genova, Istituto Gaslini, has no relevant financial relationships to disclose.
See Profile
Antonella Riva MD PhD

Dr. Riva of the University of Genoa received a travel grant from Jazz Pharmaceutical as a guest speaker.
See Profile

Editor

Solomon L Moshé MD

Dr. Moshé of Albert Einstein College of Medicine has no relevant financial relationships to disclose.
See Profile

Former Authors

Frederick Andermann MD
Andrew N Wilner MD FACP
Eva Andermann MD PhD
C P Panayiotopoulos MD PhD

Patient Profile

Age range of presentation: 6 to 18 years
Sex preponderance: male=female
Heredity: heredity typical

heredity may be a factor

autosomal recessive
Population groups selectively affected: Finns (Finland)

North Africans (Algeria, Tunisia)
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-10: Generalized idiopathic epilepsy and epileptic syndromes: G40.3
OMIM: Myoclonic epilepsy of Unverricht and Lundborg: #254800

Cystatin B (CSTB): *601145

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Progressive myoclonic epilepsy type 1

Differential Diagnosis

Myoclonus epilepsy and ataxia due to potassium channel mutation
Lafora body disease
sialidosis
neuronal ceroid lipofuscinoses
cherry-red spot myoclonus syndrome
- Spielmeyer-Vogt-Sjögren
- Batten disease
- myoclonus epilepsy with ragged-red fibers
- MELAS syndrome
- juvenile neuroaxonal dystrophy
- neuronopathic form of Gaucher disease
- atypical inclusion-body disease
- renal failure myoclonus syndrome

Also Relevant

Ataxia
Childhood movement disorders
Epilepsy
Levetiracetam
Myoclonic seizures
- Myoclonic status epilepticus
- Myoclonus
- Nondominant hereditary ataxias
- Perampanel
- Progressive myoclonus epilepsies
- Visual-sensitive epilepsies
- Zonisamide

Clinical Categories

Epilepsy & Seizures

Patient Handouts

Web References

Guidelines

Clinical Trials

Testing

Unverricht-Lundborg Disease

Progressive myoclonic epilepsy type 1

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Table 1. Etiology of Progressive Myoclonic Epilepsy Type 1 (EPM1)

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Outcomes

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Anti-LGI1 encephalitis

Self-limited (familial) neonatal epilepsy

Epilepsy with auditory features

Alcohol withdrawal seizures

Epileptic lesions due to malformation of cortical development

Epileptic spasms

Sleep and epilepsy

Neocortical temporal lobe seizures

This is an article preview.
Start a Free Account
to access the full version.